Dr. Kruszewski states that the citalopram group experienced more adverse side effects and had a higher dropout rate than the placebo group. This is not really correct. In fact, a majority of the subjects in both the citalopram and placebo arms mentioned at least one side effect, and the difference in the proportions who reported any side effects was small and statistically insignificant (χ2=1.12, df=1, N=24, exact p=0.48; effect size: φ=0.18). The difference in dropout rates was also small and insignificant (χ2=1.13, df=1, N=24, exact p=0.29; effect size: φ=0.18). Figure 2 on page 148, with the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale, shows that the subjects who were randomly assigned to citalopram tended to have lower side effect scores during treatment. As a whole, these data support the tolerability of citalopram in this population.